2025-524594-16-00招募中1 期
A Phase I study to evaluate the safety and dosimetry of imaging with 68Ga-OncoACP3 in prostate cancer.
Philogen S.p.A.2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2026年4月30日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
- 试验地点
- 2
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Jacqueline Mock
Scientific
Philogen S.p.A.
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A phase 1/2a study to evaluate the dose, safety, tolerability, and efficacy of an intraperitoneal α-emitting radionuclide therapy (Radspherin®) in subjects with peritoneal carcinomatosis from colorectal carcinoma following hyperthermic intraperitoneal chemotherapy2024-511853-23-00Oncoinvent ASA54
招募中
2 期
Phase I/II study to determine the safety and efficacy of Ribociclib in combination with hormone therapy and hypofractionated radiotherapy in breast cancer, with positive hormone receptors and negative HER2 status, in newly diagnosed, not immediately operable (or wishing to avoid surgery), elderly patientbreast cancer2022-501527-24-00Centre Antoine Lacassagne85
招募中
1 期
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid TumorsNCT07278479Molecular Partners AG138
招募中
1 期
Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple MyelomaMultiple Myeloma and Other Plasma Cell NeoplasmsNCT07529782Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.15
尚未招募
1 期
LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS MutationNCT07391566Luye Pharma Group Ltd.99